Literature DB >> 24107290

Challenges of cognitive research in neurofibromatosis type 1.

Maria T Acosta1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24107290     DOI: 10.1016/S1474-4422(13)70179-0

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  4 in total

1.  Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1.

Authors:  Thijs van der Vaart; André B Rietman; Ellen Plasschaert; Eric Legius; Ype Elgersma; Henriëtte A Moll
Journal:  Neurology       Date:  2015-10-30       Impact factor: 9.910

2.  Neurofibromatosis Type 1 Implicates Ras Pathways in the Genetic Architecture of Neurodevelopmental Disorders.

Authors:  Jessica A Kaczorowski; Taylor F Smith; Amanda M Shrewsbury; Leah R Thomas; Valerie S Knopik; Maria T Acosta
Journal:  Behav Genet       Date:  2020-02-05       Impact factor: 2.805

3.  A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.

Authors:  Carrie E Bearden; Gerhard S Hellemann; Tena Rosser; Caroline Montojo; Rachel Jonas; Nicole Enrique; Laura Pacheco; Shaun A Hussain; Joyce Y Wu; Jennifer S Ho; James J McGough; Catherine A Sugar; Alcino J Silva
Journal:  Ann Clin Transl Neurol       Date:  2016-02-22       Impact factor: 4.511

Review 4.  The impact of RASopathy-associated mutations on CNS development in mice and humans.

Authors:  Minkyung Kang; Yong-Seok Lee
Journal:  Mol Brain       Date:  2019-11-21       Impact factor: 4.041

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.